Dicot AB recently entered phase I with its drug candidate LIB-01, where the first step is to test single dosing on healthy volunteers. In parallel, the company is now starting the second part of the study, testing repeated dosing of the candidate. The first results from the study are expected in the spring.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.26 SEK | +1.76% | +1.56% | -18.24% |
May. 06 | Dicot AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 23 | Dicot AB Announces Positive Safety and Improved Efficacy Results from Phase 1 Study | CI |
1st Jan change | Capi. | |
---|---|---|
-18.24% | 19.81M | |
+40.15% | 723B | |
+34.28% | 595B | |
-3.74% | 369B | |
+20.42% | 332B | |
+2.94% | 282B | |
+17.02% | 244B | |
+9.31% | 208B | |
-5.07% | 205B | |
+0.36% | 168B |
- Stock Market
- Equities
- DICOT Stock
- News Dicot AB
- Dicot AB Initiates Repeated Dosing in Phase I Study